A new biomarker panel taken 12 weeks after initiating treatment with abiraterone acetate plus prednisone can predict prognosis at 2 years in men with mCRPC, a recent analysis of the phase III COU-AA-30 pivotal trial demonstrated.
Patrice Olson
Articles by Patrice Olson
A post-hoc analysis of the VELOUR trial demonstrated additional improvements in both overall survival (OS) and progression-free survival (PFS) in favor of aflibercept plus FOLFIRI in patients with mCRC.
Latest Updated Articles
Additional OS and PFS Benefits With Aflibercept in Post-Hoc VELOUR AnalysisPublished: December 3rd 2013 | Updated:
Biomarkers at 12 Weeks Predict Prognosis in mCRPC at 2 YearsPublished: December 5th 2013 | Updated: